Shanghai Fosun Pharmaceutical acquired an option to secure exclusive rights to Aribio’s oral phase III-stage Alzheimer’s disease therapy AR-1001 in a deal that can scale to $4.7 billion. Fosun will pay $60 million upfront for the option, with total consideration dependent on later milestones under the license agreement. The structure reinforces Fosun’s playbook of buying staged exposure to late-stage neurodegeneration assets before committing to full commercialization. It also highlights continued interest from China- and Asia-based groups in Alzheimer’s drug candidates reaching late clinical phases. For Aribio, the transaction provides significant capital visibility while preserving optionality on the development and regulatory path for AR-1001, which is already in phase III.